OMass Therapeutics raises $310M in Series C led by Bain Capital Life Sciences, Forbion, and Novo Holdings to advance its MC2 receptor antagonist into phase 2 development.
Amount Raised
$310 Million
Round Type
Series C
United StatesBiotechnologyInvestors
Description
OMass Therapeutics announced a $310 million Series C funding round, marking the second-largest European biotech raise of 2026. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, and existing backers including GV (Alphabet's VC arm), Syncona, Sanofi Ventures, the British Business Bank, and the University of Oxford. The company plans to use proceeds to advance its lead candidate OMS1620 through phase 2 trials in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. CEO Ros Deegan described the financing as a 'fantastic milestone' on the journey to establish 'Britain's Big Biotech.'
Quick answer
OMass raised $310 Million in a Series C round, dated October 15, 2026. Investors: GV, Jefferson Life Sciences, SV Health Investors, Novo Holdings, Forbion, Bain Capital Life Sciences, British Business Bank and Syncona. OMass is based in United States.
- How much did OMass raise?
- OMass raised $310 Million in a Series C round on October 15, 2026.
- Who invested in OMass?
- GV, Jefferson Life Sciences, SV Health Investors, Novo Holdings, Forbion, Bain Capital Life Sciences, British Business Bank and Syncona are named as investors in this round.
- What does OMass do?
- It uses a combination of novel biochemistry, native mass spectrometry and custom chemistry.
- Where is OMass based and how big is it?
- OMass is based in United States. Fundz records about 11 employees.
- Who are the decision-makers at OMass?
- Fundz holds 2 contacts at OMass, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as OMass that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- XTPL raised $6.5M on November 13, 2026.
- BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
- PAM2L Biotechnologies raised an undisclosed amount on November 12, 2026.
- Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
- Biomatter raised $18M (Series A) on November 12, 2026.
Who to call at OMass, and when
A new round usually means OMass is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day OMass raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at OMass, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at OMass. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment OMass raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
OMass raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.